FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306290781> ?p ?o ?g. }

• W4306290781 abstract "Abstract Introduction Tafamidis inhibits progression of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) by binding TTR tetramer and inhibiting its dissociation to monomers which can denature and result in amyloid fibril formation and deposition in cardiac tissue. Purpose While the phase 3 ATTR-ACT clinical data clearly demonstrated efficacy, quantification of TTR stabilization in patients and the degree to which the approved dose captures the full potential of the mechanism has yet to be assessed. Methods Isothermal titration calorimetry and subunit fraction exchange were used to determine affinities to the two binding sites on TTR. These values were used to develop a model of tafamidis binding to TTR in plasma that was applied to individual patient data to calculate TTR binding site occupancy and the change in total TTR levels induced by TTR stabilization. Population pharmacodynamic (PD) models were developed for three measures of disease progression, plasma NT-proBNP levels, Kansas City Cardiomyopathy Questionnaire – Overall Score (KCCQ-OS), and six-minute walk test (6MWT) distance, to evaluate patient response with the degree of TTR occupancy. Results In vitro binding data of wild-type TTR confirmed tafamidis binds two sites of TTR with negative cooperativity and provided precise estimates of the binding affinity to TTR and albumin. Modeling individual patient data of tafamidis exposure and increased TTR plasma levels using the in vitro derived binding affinity values confirms single site binding is consistent with complete tetramer stabilization. Patients given 80 mg tafamidis meglumine, the clinically approved dose for ATTR-CM, had a 92% reduction in unbound, unstabilized TTR, which correlated with a 53% decrease in NT-proBNP elevation, a 56% decrease in KCCQ-OS worsening and a 49% reduced decline in the 6MWT. For 100% receptor occupancy and stabilization, the expected effects on these measures are 58%, 61%, and 54% for NT-proBNP, KCCQ-OS, and 6MWT, respectively. Conclusions These results demonstrate a quantitative relationship between TTR stabilization, the mechanism of action of tafamidis, and accepted laboratory and patient-based outcomes in ATTR-CM. These results also support the value of TTR stabilization as a clinically beneficial treatment option which maintains the protein in its physiologically active form within the body. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): This study was sponsored by Pfizer." @default.
• W4306290781 created "2022-10-15" @default.
• W4306290781 creator A5002080538 @default.
• W4306290781 creator A5008601901 @default.
• W4306290781 creator A5013278963 @default.
• W4306290781 creator A5016158013 @default.
• W4306290781 creator A5070759151 @default.
• W4306290781 creator A5089558811 @default.
• W4306290781 date "2022-10-01" @default.
• W4306290781 modified "2023-09-27" @default.
• W4306290781 title "Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients" @default.
• W4306290781 doi "https://doi.org/10.1093/eurheartj/ehac544.956" @default.
• W4306290781 hasPublicationYear "2022" @default.
• W4306290781 type Work @default.
• W4306290781 citedByCount "0" @default.
• W4306290781 crossrefType "journal-article" @default.
• W4306290781 hasAuthorship W4306290781A5002080538 @default.
• W4306290781 hasAuthorship W4306290781A5008601901 @default.
• W4306290781 hasAuthorship W4306290781A5013278963 @default.
• W4306290781 hasAuthorship W4306290781A5016158013 @default.
• W4306290781 hasAuthorship W4306290781A5070759151 @default.
• W4306290781 hasAuthorship W4306290781A5089558811 @default.
• W4306290781 hasBestOaLocation W43062907811 @default.
• W4306290781 hasConcept C107824862 @default.
• W4306290781 hasConcept C121157162 @default.
• W4306290781 hasConcept C126322002 @default.
• W4306290781 hasConcept C181199279 @default.
• W4306290781 hasConcept C185592680 @default.
• W4306290781 hasConcept C2778886173 @default.
• W4306290781 hasConcept C55493867 @default.
• W4306290781 hasConcept C71924100 @default.
• W4306290781 hasConcept C98274493 @default.
• W4306290781 hasConceptScore W4306290781C107824862 @default.
• W4306290781 hasConceptScore W4306290781C121157162 @default.
• W4306290781 hasConceptScore W4306290781C126322002 @default.
• W4306290781 hasConceptScore W4306290781C181199279 @default.
• W4306290781 hasConceptScore W4306290781C185592680 @default.
• W4306290781 hasConceptScore W4306290781C2778886173 @default.
• W4306290781 hasConceptScore W4306290781C55493867 @default.
• W4306290781 hasConceptScore W4306290781C71924100 @default.
• W4306290781 hasConceptScore W4306290781C98274493 @default.
• W4306290781 hasIssue "Supplement_2" @default.
• W4306290781 hasLocation W43062907811 @default.
• W4306290781 hasOpenAccess W4306290781 @default.
• W4306290781 hasPrimaryLocation W43062907811 @default.
• W4306290781 hasRelatedWork W1091736998 @default.
• W4306290781 hasRelatedWork W1965976665 @default.
• W4306290781 hasRelatedWork W1968925833 @default.
• W4306290781 hasRelatedWork W2068111204 @default.
• W4306290781 hasRelatedWork W2080642878 @default.
• W4306290781 hasRelatedWork W2082438387 @default.
• W4306290781 hasRelatedWork W2115845634 @default.
• W4306290781 hasRelatedWork W2140076366 @default.
• W4306290781 hasRelatedWork W2151392910 @default.
• W4306290781 hasRelatedWork W2157865564 @default.
• W4306290781 hasVolume "43" @default.
• W4306290781 isParatext "false" @default.
• W4306290781 isRetracted "false" @default.
• W4306290781 workType "article" @default.